Why Traditional Approaches Often Fall Short
Designing an effective sales compensation plan for a rare disease product is fundamentally different from designing one for a product with a broad patient population. Rare disease sales organizations are typically small, with representatives covering large geographies and highly specialized customer groups. Opportunities are fewer, each interaction is more valuable, and mistakes in compensation design can be costly.
As a result, rare disease products often require customized sales compensation solutions rather than traditional incentive plans adapted from primary care or specialty pharmaceutical models.
At The Marketing Advantage (TMA), we have found that the optimal compensation plan is largely determined by six key market characteristics.
The Six Key Market Characteristics of Rare Disease Compensation Design
The size of the patient population largely determines the flexibility available in compensation design. Larger patient populations can support more traditional sales incentive approaches, while smaller populations often require alternative methodologies.
Patient Population Size
Target Concentration and Difficulty of Diagnosis
The concentration of specialists and the complexity of identifying patients can either expand or significantly restrict the universe of promotional opportunities.
Treatment Duration
Whether a therapy is chronic, lifelong, episodic, or a one-time treatment directly impacts the importance of patient retention and the sustainability of sales growth.
Data Availability and Accuracy
The quality of claims data, prescription data, and competitive intelligence influences both the fairness and credibility of the compensation plan.
Competitive And Alternative Treatment Environment
The presence of competing therapies or alternative treatment approaches often determines how heavily plans should reward advocacy and market development activities.
Treatment Administration Complexity
The complexity of treatment administration impacts where, how, and with whom sales representatives must engage to drive adoption.
Together, these six factors influence both the structure and the details of a rare disease sales compensation plan.
Surprisingly, many large BioPharma companies treat their rare disease products (if they have larger population sizes) much like they do regular BioPharma products. In fact, the three most commonly employed sales compensation plans are not truly tailored for rare disease:
Common Compensation Plans Used in Larger Rare Disease Markets
1. FORCED RANKING BASED ON UNITS AND UNIT GROWTH
Administration: Quarterly
- Easy and inexpensive to administer.
- Particularly attractive for organizations managing multiple rare disease products.
- Plan costs are relatively predictable.
Advantages
- Often viewed as inequitable.
- Large-volume territories and small-volume territories frequently end up in the middle of the rankings.
- Typically does not maximize sales performance.
Disadvantages
Common Outcomes
- Higher turnover compared with more sophisticated incentive approaches.
- Large-volume territories rarely finish at the top unless growth metrics receive significant weighting.
2. GOAL-BASED PLANS USING PRIOR SALES PLUS GROWTH EXPECTATIONS
Administration: Quarterly
- Goals are usually set by applying unit or percentage growth to historical performance, which is easy to calculate.
- Payout curve design provides leverage to manage motivation.
Advantages
- Total plan cost is difficult to predict.
- Unrealistic national goals can quickly create frustration throughout the sales force.
Disadvantages
Common Outcomes
- Wide attainment distributions across territories.
- Representatives in lower-opportunity territories often struggle to achieve goals consistently.
- Persistent underperformance can contribute to turnover.
Administration: Quarterly (Single-tier or two-tier structures with consistent commission rates)
3. STRAIGHT COMMISSION PLANS
- Representatives clearly understand how their efforts translate into earnings.
- Strong alignment between sales activity and compensation.
- Frequently drives strong sales performance.
Advantages
- Establishing the correct commission rate can be challenging.
- Incentive expenses are difficult to forecast.
Disadvantages
Common Outcomes
- Some territories may be overcompensated relative to opportunity.
- High-performing representatives may feel underpaid if rates are not calibrated correctly.
Why Customization Matters
While these approaches are commonly used, they are rarely optimal. Rare disease markets are highly diverse, and a compensation plan that succeeds for one product may be ineffective for another.
The most successful plans are typically built around the unique market dynamics of the product.
A Real-World Example
Consider a rare disease product with the following characteristics:
Environment
Complexity
In this market, the organization's ultimate objective was to drive sales growth. However, because physicians had multiple treatment alternatives available, the more immediate challenge was increasing physician advocacy and adoption of the therapy.
Incentive Strategy: Drive Advocacy Through Market Penetration
The company maintained a clearly defined target list and could identify which specialists were currently prescribing the therapy and which were not. Rather than rewarding representatives solely for generating additional prescriptions, the incentive plan focused on expanding adoption among previously non-prescribing specialists.
The primary performance objective became increasing the percentage of target physicians who converted from non-prescribers to prescribers while maintaining engagement among existing adopters. This approach aligned the incentive plan more directly with the business challenge facing the brand.
To illustrate, consider two territories that each contain 100 targeted specialists:
Territory A: 70 current prescribers, 30 non-prescribers
Territory B: 40 current prescribers, 60 non-prescribers
Territory B contains twice as many non-prescribers as Territory A.
Under a simple "new prescriber" measure, Territory B would have a significant structural advantage. By focusing instead on the percentage of non-prescriber penetration, both territories are measured against the opportunity remaining in their market.
This distinction is particularly important in rare disease markets. Territories with already high adoption rates often face the greatest challenges because the remaining physicians may be the most difficult to influence. A compensation plan based solely on absolute growth can unintentionally penalize representatives working in highly penetrated markets.
By measuring success as a percentage of remaining opportunity, the plan creates a more equitable comparison across territories while continuing to reward market expansion.
Conclusion
Rare disease sales compensation is uniquely challenging because no two markets are alike. Patient population size, specialist concentration, treatment characteristics, data availability, competitive dynamics, and treatment complexity all influence what constitutes an effective incentive strategy.
Organizations that rely on standardized compensation models often fail to align incentives with the realities of their market. The most effective rare disease compensation plans are those specifically designed around the unique characteristics of the product and the opportunities available to the sales team.
In our next article, we will examine each of TMA's Six Key Rare Disease Characteristics in greater detail and explore how they shape the nuances of successful rare disease sales compensation plans.